Upcoming Journal Club Presentation:

Journal Club (11)...coming soon...

Past Journal Club Presentations:

Tuesday 13th April 2021 | 12.30pm EDT | 5.30pm UK

Distinct trajectories of antidepressant response to intravenous ketamine

O'Brien B, Lijffijt M, Lee J, Kim YS, Wells A, Murphy N, Ramakrishnan N, Swann AC, Mathew SJ. Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 Mar 9;286:320-329. doi: 10.1016/j.jad.2021.03.006. Epub ahead of print. PMID: 33770540.
 Presenter: Brittany O'Brien, Ph.D., Assistant Professor, Psychiatry and Behavioral Sciences Baylor College of Medicine Houston, TX, USA

Tuesday 23rd March 2021 | 1.30pm EDT | 5.30pm UK

Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo- Controlled, Proof-of-Concept Trial

Domany Y, McCullumsmith CB. Arch Suicide Res. 2021 Feb 14:1-16. doi: 10.1080/13811118.2021.1878078. Epub ahead of print. PMID: 33583341
 Presenter: Yoav Domany, MD, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, USA; Department of Psychiatry, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Tuesday 9th March 2021 | 12.30pm EST | 5.30pm UK

Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder

Lundin NB, Sepe-Forrest L, Gilbert JR, Carver FW, Furey ML, Zarate CA Jr, Nugent AC. J Affect Disord. 2021 Jan 15;279:239-249. doi: 10.1016/j.jad.2020.10.007. Epub 2020 Oct 7. PMID: 33074143

Presenter: Allison C Nugent, Ph.D., Director of the Magnetoencephalography (MEG) Core Facility, National Institute of Mental Health, Bethesda, MD, USA

Tuesday 23rd February 2021 | 12.30pm EST | 5.30pm UK

Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers

Torsten Passie, Hans-Anton Adams, Frank Logemann, Simon D Brandt, Birgitt Wiese, Matthias Karst. Eur Neuropsychopharmacol. 2021 Jan 21;S0924-977X(21)00007-9 .PMID: 33487513

Presenter: Torsten Passie M.D., Ph.D., Professor of Psychiatry and Psychotherapy Goethe-University Franfurt/Main, Germany; (Visiting Scientist) Hannover Medical School, Germany (affiliate)

Tuesday 9th February 2021 12.30pm EST; 5.30pm UK

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. 

Siegel JS, Palanca BJA, Ances BM, Kharasch ED, Schweiger JA, Yingling MD, Snyder AZ, Nicol GE, Lenze EJ, Farber NB.  Psychopharmacology (Berl). 2021 Jan 22. PMID: 33483802.

Presenter: Josh Siegel, MD, PhD, Psychiatry Resident, Washington University St Louis, USA

Tuesday 12th January 2021 12.30pm EST; 5.30pm UK

An RCT of repeated ketamine administration for chronic post-traumatic stress disorder

Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Bevilacqua L, Glasgow AM, Brallier J, Pietrzak RH, Murrough JW, Charney DS. 

 Am J Psychiatry. 2021 Jan 5: doi: 10.1176/appi.ajp.2020.20050596. Epub ahead of print. PMID: 33397139

Presenter: Adriana Feder, Associate Professor, Icahn School of Medicine, Mount Sinai, New York 

Tuesday 10th November 2020 12.30pm EST; 5.30pm UK

Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. 
Morris LS, Costi S, Tan A, Stern ER, Charney DS, Murrough JW. Neuropsychopharmacology (2020), 45(6):975-981.  PMID: 31896116
Presenter: Laurel Morris, Assistant Professor, Icahn School of Medicine, Mount Sinai, New York 

Tuesday 24th November 2020 12:30pm EST; 5.30pm UK

Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. 
Sakurai H, Jain F, Foster S, Pedrelli P, Mischoulon D, Fava M, Cusin C. J Affect Disord. 2020 Nov 1;276:660-666.
PMID: 32871698
Presenter: Cristina Cusin,  Assistant Professor of Psychiatry, Massachusetts General Hospital

Tuesday 8th December 2020 12:30pm EST; 5.30pm UK

The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. 
McIntyre RS, Rodrigues NB, Lipsitz O, Nasri F, Gill H, Lui LM, Subramaniapillai M, Kratiuk K, Teopiz K, Ho R, Lee Y, Mansur RB, Rosenblat JD.  J Psychopharmacol. 2020 Oct 11 Epub ahead of print. 
PMID: 33040665
Presenter: Roger McIntyre,  Professor of Psychiatry and Pharmacology, University of Toronto

Tuesday 22nd December 2020 12:30pm EST; 5.30pm UK

Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine. 
Chen BK, Luna VM, LaGamma CT, Xu X, Deng SX, Suckow RF, Cooper TB, Shah A, Brachman RA, Mendez-David I, David DJ, Gardier AM, Landry DW, Denny CA.  Neuropsychopharmacology. 2020 Aug;45(9):1545-1556. 
PMID: 32417852
Presenter: Christine Denny, Assistant Professor of Clinical Neurobiology (in Psychiatry), Columbia University, New York

About Ketamine International Journal Club

  • A series of free, short, 30-minute webinars held every two weeks
  • Held on 2nd and 4th Tuesdays at 12:30pm EST (usually 9:30am Pacific, 5:30pm GMT, 11:00pm Indian Standard)
  • Authors present for 15 minutes followed by 15 minutes answers to written Q&A
  • Authors may additionally stay for a further 30 minutes of interactive discussion on a separate link
  • Recently published papers on ketamine and related compounds for the treatment of psychiatric disorders
  • A balance of RCTs, animal work, experimental medicine / human mechanism, case series
  • Recordings will be made available through the Ketamine Conference website to all registrants
  • Intended audience: clinicians, clinical and pre-clinical scientists, industry, policy makers
  • Independent of industry funding
  • Programmed and run by academic clinicians at Oxford and psychiatric trainees
  • Organisational support from the American Society of Ketamine Physicians, Psychotherapists & Practitioners
  • Complements Ketamine2021 virtual conference (25-26th March, 2021) and ASKP3 conference (October/November, 2021)

    • Organisers

    Rupert McShane Associate Professor, Department of Psychiatry, University of Oxford, UK
    Sara Costi Wellcome Trust Doctoral Training Fellow, Harmer Group Department of Psychiatry, University of Oxford
    Jacek Lindner Psychiatric Trainee, NHS Greater Glasgow & Clyde, UK